AG
SGTX

Artal Group’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Artal Group’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-21,231
Closed -$139K – 144
2022
Q3 		$139K Hold
21,231
– – 0.01% 135
2022
Q2 		$229K Hold
21,231
– – 0.01% 132
2022
Q1 		$406K Hold
21,231
– – 0.02% 133
2021
Q4 		$762K Hold
21,231
– – 0.02% 142
2021
Q3 		$1.56M Hold
21,231
– – 0.03% 138
2021
Q2 		$2.96M Hold
21,231
– – 0.06% 129
2021
Q1 		$6.17M Hold
21,231
– – 0.11% 118
2020
Q4 		$13.3M Buy
+21,231
New +$9.63M 0.28% 81

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $2.32B AUM 30.12% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group's SGTX Position: Q4 2022 in Review

Artal Group sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q4 2022, closing a stake of 21,231 shares — an estimated $139K sold.

Artal Group first reported a position in SGTX in Q4 2020 and held it in 8 quarters. The position peaked at $13.3M in Q4 2020. 32 funds tracked by Wall St. Rank hold SGTX as of Q4 2022.

  • Artal Group reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Artal Group sold 21,231 Sigilon Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $139K.
  • Artal Group first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
  • Artal Group's Sigilon Therapeutics, Inc. Common Stock position peaked at $13.3M in Q4 2020.
  • 32 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.